There are big medical advancements for triple-negative breast cancer coming in 2025!
Triple-negative is the most aggressive and deadliest form of breast cancer. Now, the next phase of research into a vaccine is getting ready to begin.
EXPLAINER: Understanding breast cancer risk factors, and answering other questions Houstonians might have
Dr. Amit Kumar, CEO of Anixa Biosciences, the company developing this vaccine, says a total of 27 women received the breast cancer vaccine and the results are very promising.
“We saw an immune response in the majority of women. Meaning, the vaccine was teaching their immune systems to target cancer cells. The key point is that while we were getting really good responses and the best responses that we’ve seen in any vaccine trial so far, the ability to determine how efficacious this is going to be done in a phase 2 trial,” explained Dr. Kumar.
Right now the trial is being conducted at the Cleveland Clinic in Ohio. Phase 2 will be the first time the study expands nationwide.
Phase 2 will include newly diagnosed women to see if the vaccine can shrink the size of their tumor. It will also examine women who have a high chance of recurrence of their breast cancer.
SUGGESTED: During Men’s Breast Cancer Awareness Week, survivor Charlie Morris shares his story with KPRC 2
Dr. Amit has worked with the White House and this breast cancer vaccine research is funded by the Department of Defense.
